Janus Henderson Group PLC Increases Stock Holdings in STERIS plc $STE

Janus Henderson Group PLC raised its position in shares of STERIS plc (NYSE:STE) by 25.7% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,863,139 shares of the medical equipment provider’s stock after purchasing an additional 380,504 shares during the quarter. Janus Henderson Group PLC’s holdings in STERIS were worth $411,995,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in STE. Jones Financial Companies Lllp lifted its stake in shares of STERIS by 46.1% in the 1st quarter. Jones Financial Companies Lllp now owns 1,106 shares of the medical equipment provider’s stock worth $251,000 after purchasing an additional 349 shares during the period. Goldman Sachs Group Inc. boosted its holdings in shares of STERIS by 32.3% in the first quarter. Goldman Sachs Group Inc. now owns 242,732 shares of the medical equipment provider’s stock worth $55,015,000 after buying an additional 59,264 shares during the last quarter. Empowered Funds LLC grew its position in STERIS by 16.1% during the first quarter. Empowered Funds LLC now owns 2,303 shares of the medical equipment provider’s stock valued at $522,000 after buying an additional 319 shares during the period. Woodline Partners LP grew its position in STERIS by 40.0% during the first quarter. Woodline Partners LP now owns 8,300 shares of the medical equipment provider’s stock valued at $1,881,000 after buying an additional 2,372 shares during the period. Finally, Jane Street Group LLC increased its holdings in STERIS by 38.9% during the first quarter. Jane Street Group LLC now owns 20,716 shares of the medical equipment provider’s stock valued at $4,695,000 after buying an additional 5,803 shares during the last quarter. Hedge funds and other institutional investors own 94.69% of the company’s stock.

Insider Transactions at STERIS

In related news, CEO Daniel A. Carestio sold 1,374 shares of STERIS stock in a transaction on Friday, June 5th. The shares were sold at an average price of $212.00, for a total transaction of $291,288.00. Following the transaction, the chief executive officer owned 63,647 shares in the company, valued at approximately $13,493,164. The trade was a 2.11% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard C. Breeden sold 1,481 shares of the company’s stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $209.51, for a total transaction of $310,284.31. Following the completion of the transaction, the director directly owned 38,964 shares of the company’s stock, valued at $8,163,347.64. This represents a 3.66% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 7,328 shares of company stock valued at $1,554,051 over the last three months. Corporate insiders own 1.12% of the company’s stock.

Analyst Ratings Changes

STE has been the topic of several recent research reports. Piper Sandler reiterated an “overweight” rating and issued a $270.00 price target on shares of STERIS in a research report on Thursday, May 21st. UBS Group began coverage on shares of STERIS in a research report on Tuesday. They set a “buy” rating and a $275.00 price objective for the company. Wall Street Zen lowered STERIS from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 6th. Weiss Ratings cut STERIS from a “hold (c+)” rating to a “hold (c)” rating in a report on Wednesday, May 27th. Finally, KeyCorp decreased their target price on STERIS from $291.00 to $269.00 and set an “overweight” rating on the stock in a report on Wednesday, May 13th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, STERIS presently has a consensus rating of “Moderate Buy” and a consensus price target of $277.25.

STERIS Trading Down 1.5%

Shares of NYSE:STE opened at $231.32 on Friday. The stock has a 50 day moving average of $212.75 and a 200 day moving average of $226.54. The company has a market cap of $22.54 billion, a PE ratio of 29.17 and a beta of 0.92. The company has a current ratio of 2.09, a quick ratio of 1.54 and a debt-to-equity ratio of 0.25. STERIS plc has a 12-month low of $195.14 and a 12-month high of $269.44.

STERIS (NYSE:STE) last released its earnings results on Monday, May 11th. The medical equipment provider reported $2.83 EPS for the quarter, missing analysts’ consensus estimates of $2.86 by ($0.03). STERIS had a return on equity of 14.15% and a net margin of 13.18%.The firm had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.59 billion. During the same quarter in the previous year, the business posted $2.74 EPS. STERIS’s revenue was up 6.7% on a year-over-year basis. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. As a group, equities research analysts expect that STERIS plc will post 11.18 EPS for the current year.

STERIS Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 25th. Stockholders of record on Friday, September 4th will be paid a $0.69 dividend. This represents a $2.76 dividend on an annualized basis and a dividend yield of 1.2%. This is a boost from STERIS’s previous quarterly dividend of $0.63. The ex-dividend date of this dividend is Friday, September 4th. STERIS’s dividend payout ratio is currently 31.78%.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.